In wake of Covid-19 vac­cine suc­cess­es, Mod­er­na scraps an mR­NA-based an­ti­body for chikun­gun­ya virus

Mod­er­na has drawn plau­dits from around the in­dus­try and the globe for its Covid-19 vac­cine, and it re­port­ed con­tin­ued fi­nan­cial suc­cess Thurs­day in its third-quar­ter re­port. But the biotech al­so qui­et­ly an­nounced the dis­con­tin­u­a­tion of an­oth­er mR­NA pro­gram, one in which it had col­lab­o­rat­ed with DARPA.

Ex­ecs are scrap­ping Phase II plans for an an­ti­body di­rect­ed at the chikun­gun­ya virus, the com­pa­ny an­nounced Thurs­day, dis­creet­ly end­ing the de­vel­op­ment of a gov­ern­ment-part­nered prod­uct. Mod­er­na did not pro­vide a rea­son for the de­ci­sion, say­ing on­ly that a Phase I study had been com­plet­ed and full re­sults would be pub­lished “soon.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER